Pioneering 3D Human Tissues for Drug Discovery
May 21 | 2024
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
Read More »May 14 | 2024
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
Read More »May 08 | 2024
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Read More »